Merck & Co. delivered a mixed second-quarter report, beating analyst estimates for earnings while simultaneously raising its full-year revenue outlook.
The positive top-line revision was driven by robust sales growth across a slate of new products, signaling continued commercial momentum for the company’s pipeline.
However, the pharmaceutical giant lowered its profit guidance for the year.
The downgrade was attributed to a significant charge associated with its acquisition of biotech firm Terns Pharmaceuticals.
The cost reflects the financial impact of integrating the new entity, which has offset some of the operational gains from the quarter’s strong product performance.
The divergence between the revenue upgrade and profit cut highlights the transitional nature of Merck’s current strategy.